Axium Healthcare Puerto Rico is proud to announce it is now dispensing:
ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) injection use; are transthyretin-directed small interfering RNA treatments and indicated:
GIVLAARI (givosiran), injection use; is a transthyretin-directed small interfering RNA treatments and indicated:
OXLUMO (lumasiran), injection use; is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated:
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Puerto Rico Specialty Pharmacy, recently shared what access to these medicines mean for the rare disease community. “Alnylam addresses the needs of patients that historically had limited or inadequate treatment options for their diseases. With an innovative new class of medicines using a gene silencing therapy, allows patients to truly own their conditions.”
At Axium Healthcare Puerto Rico our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Rare Diseases. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare Pharmacy Puerto Rico:
At Axium Healthcare Puerto Rico, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare Puerto Rico offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare Puerto Rico services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
About Alnylam Pharmaceuticals:
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the potential treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s has developed RNAi therapeutic products which are licensed for the treatment of hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1 and primary hypercholesterolemia / mixed dyslipidemia. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information, visit www.alynylam.com.
Trademarks are owned by or licensed to Alynylam.